Abstract 228P
Background
Recent research has emphasized the pivotal role of tumor-associated macrophages (TAMs) in shaping the efficacy of anti-tumor therapies. Metabolic reprogramming is a key driver of TAM polarization, influencing their pro-tumorigenic or anti-tumorigenic phenotypes. However, the precise mechanisms by which tumor cells manipulate TAM metabolism remain elusive. We have currently discovered that agonistic anti-CD40 antibodies promote anti-tumorigenic TAM activation by enhancing mitochondrial activity and modulating fatty acid oxidation (FAO). We further investigated the interplay between mitochondrial fitness and FAO in regulating TAM immunosuppressive functions.
Methods
We conducted a series of in vitro and in vivo experiments using mouse melanoma tumor models and bone marrow-derived macrophages (BMDMs) for this study.
Results
Our findings demonstrate that lipid-accumulated TAMs exhibit impaired mitochondrial activity, exacerbating their pro-tumorigenic properties. Tumor-derived lipids influence mitochondrial dynamics in TAMs, leading to increased FAO, mitochondrial reactive oxygen species (mtROS) production, and mitophagy. These metabolic alterations collectively contribute to the pro-tumorigenic phenotype of TAMs. Moreover, our research suggests that targeting mitochondrial dynamics-associated pathways may represent a promising therapeutic strategy to reverse TAM immunosuppression and enhance anti-tumor immunity.
Conclusions
This study provides valuable insights into the intricate relationship between lipid metabolism, mitochondrial dynamics, and TAM polarization within the tumor microenvironment (TME). By elucidating how lipid metabolism interacts with mitochondrial dynamics to modulate TAM phenotypes, we aim to develop innovative therapeutic approaches targeting these pathways to improve anti-tumor responses.
Legal entity responsible for the study
The author.
Funding
National Science and Technology Council (MOST 111-2314-B-400-026-MY3).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session